Petros Pharmaceuticals Stock Net Income
| PTPIDelisted Stock | USD 0.03 0 13.35% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Petros Pharmaceuticals' long-term financial health and intrinsic value.
Petros |
Petros Pharmaceuticals Company Net Income Analysis
Petros Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Petros Pharmaceuticals Net Income | (14.32 M) |
Most of Petros Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Petros Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Petros Pharmaceuticals reported net income of (14.32 Million). This is 104.2% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 102.51% higher than that of the company.
Petros Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Petros Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Petros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Petros Pharmaceuticals by comparing valuation metrics of similar companies.Petros Pharmaceuticals is currently under evaluation in net income category among its peers.
Petros Fundamentals
| Return On Equity | -5.71 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (2.80) % | ||||
| Operating Margin | (2.41) % | ||||
| Current Valuation | (1.42 M) | ||||
| Shares Outstanding | 2.14 M | ||||
| Shares Owned By Insiders | 7.39 % | ||||
| Shares Owned By Institutions | 6.79 % | ||||
| Number Of Shares Shorted | 12.35 M | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 0.05 X | ||||
| Revenue | 5.11 M | ||||
| Gross Profit | 3.9 M | ||||
| EBITDA | (10.81 M) | ||||
| Net Income | (14.32 M) | ||||
| Cash And Equivalents | 13.3 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 7.39 M | ||||
| Debt To Equity | 0.31 % | ||||
| Current Ratio | 3.10 X | ||||
| Book Value Per Share | (17.73) X | ||||
| Cash Flow From Operations | (2.6 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (63.15) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 2.2 | ||||
| Market Capitalization | 265.45 K | ||||
| Total Asset | 10.64 M | ||||
| Retained Earnings | (113.21 M) | ||||
| Working Capital | (10.73 M) | ||||
| Net Asset | 10.64 M |
About Petros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Petros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Petros Pink Sheet
If you are still planning to invest in Petros Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Petros Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |